Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Short Interest Update

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) was the recipient of a large decrease in short interest during the month of February. As of February 27th, there was short interest totaling 14,323 shares, a decrease of 56.8% from the February 12th total of 33,185 shares. Based on an average trading volume of 31,057 shares, the days-to-cover ratio is presently 0.5 days. Approximately 0.3% of the company’s shares are sold short. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 31,057 shares, the days-to-cover ratio is presently 0.5 days.

Analyst Ratings Changes

A number of equities analysts recently commented on NEUP shares. Zacks Research upgraded Neuphoria Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 3rd. HC Wainwright reduced their price target on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, December 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Finally, Wall Street Zen downgraded shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, November 23rd. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Stock Performance

Shares of NASDAQ:NEUP traded down $0.02 during trading hours on Thursday, reaching $4.72. The stock had a trading volume of 31,220 shares, compared to its average volume of 45,710. Neuphoria Therapeutics has a 1 year low of $3.64 and a 1 year high of $21.40. The stock has a market capitalization of $25.44 million, a price-to-earnings ratio of -1.07 and a beta of 0.50. The firm’s 50 day moving average is $4.16 and its 200-day moving average is $6.89.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings data on Friday, February 13th. The company reported ($0.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.21). Analysts forecast that Neuphoria Therapeutics will post -1.56 EPS for the current year.

Institutional Trading of Neuphoria Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd acquired a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at $47,000. Ikarian Capital LLC purchased a new position in shares of Neuphoria Therapeutics in the 4th quarter valued at approximately $184,000. Boothbay Fund Management LLC acquired a new position in shares of Neuphoria Therapeutics in the fourth quarter valued at approximately $54,000. Bridgeway Capital Management LLC purchased a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth approximately $57,000. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Neuphoria Therapeutics during the fourth quarter worth $116,000. Institutional investors and hedge funds own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.